PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 14, 2026PLoS Computational BiologyOpen Access

Multi-omics and network pharmacology identify IGFBP1 as an m6A-Epigenetic target of pueraria in NSCLC therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRui LiDHDongmei HuYLYong-Li Liu

Discussion

Loading...

Member takes

Overview

Integration of multi-omics with pharmacology reveals IGFBP1 as a key target in NSCLC therapy, suggesting new treatment pathways.

Key Points

  • This research identifies IGFBP1 as a critical target in NSCLC, exploring its connection to m6A modification and Pueraria pharmacology.
  • Conducted multi-omics clustering of 1,661 NSCLC samples
  • Developed a 19-gene prognostic signature using Cox regression
  • Validated gene expression via scRNA-seq and RT-qPCR in NSCLC cell lines
  • Performed molecular docking and dynamics simulations on Pueraria compounds targeting IGFBP1
  • Identified three distinct m6A modification patterns in NSCLC samples
  • Established a prognostic model that correlates with immune infiltration and patient survival
  • Confirmed IGFBP1 expression in NSCLC tissues
  • Demonstrated stable binding of Pueraria compounds to IGFBP1 in simulations

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69b4ba1818185d8a39802977https://doi.org/10.1371/journal.pcbi.1014050
View Full Paper
Ask AI
Bookmark
Share